Greg Freiherr, Industry Consultant
Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | Radiology Imaging | June 08, 2016

Why Developing Multiple Screening Technologies is a Must

MR

MR prostate image courtesy of Siemens Healthineers

Effective screening may be the key to America’s future. Only by catching disease early, before disease can injure the patient and impose financial penalties from lost work and medical expenses, can America achieve its dual goals of high-quality healthcare at low cost. Cancer, more than any other disease, exemplifies the promise and challenge.

Modern mammography screening may reduce deaths from breast cancer up to 28 percent. This success raises hope that similar gains might be made against other cancers. The use of computed tomography (CT) for lung screening and magnetic resonance imaging (MRI) for examining the prostate illustrate the two extremes of how this might be approached.

Low-dose CT lung screen has come in the wake of failed tests, namely chest X-rays and sputum cytology, neither of which has decreased lung cancer mortality. In contrast, prostate MRI is being pursued as one of several interlocking technologies and techniques that include digital exams performed by gloved physicians, PSA blood tests and ultrasound follow-up.

The latest MR advance is non-invasive, thanks to surface coils whose use streamlines patient set-up and accelerates scans. Adding to the future potential of prostate assessment are several positron emission tomography (PET) radiotracers that show promise for identifying prostate cancer, metastatic spread and relapse. Notably new opportunities are also arising in single-photon emission computerized tomography (SPECT) and PET/MR.

Although screening, diagnosis and monitoring for prostate cancer are still very far from perfect, they exemplify where screening needs to go.

 

Know When to Fold ‘Em

Rather than depending entirely on a single imaging technology, as does CT lung screening, or heavily so, as does mammography, prostate screening is part of a multi-pronged approach that may provide the flexibility for developers to adjust their R&D and for healthcare strategists to fine tune protocols.

The advantage stems from the cautionary tale of putting all your eggs in one basket. Spreading those eggs around provides options. Just as importantly, having multiple options could help developers know when to quit — when to walk away from a technology that has gone sour and pursue more promising ones.

All too often innovators, having fallen in love with a technology, doggedly pursue it, wasting huge sums of money in the process. In the case of screening, this could do an even greater harm, delaying the development of effective screening tools.

The irony, of course, is that money can limit the development of multiple technologies, leading entrepreneurs to gamble on a “best bet.” Funding can be particularly problematic for publicly held companies, which must account for expenditures to shareholders. This is where a silent partner can come in handy. And there are few in a better position to play this role than the Federal government.

Through innovation grants, the Feds scatter seed money like a tech-savvy Johnny Appleseed. Among the sources: the Federal Laboratory Consortium for Technology Transfer, Small Business Innovation Research, Small Business Technology Transfer and Experimental Program to Stimulate Competitive Research.

Those funds too are finite — and getting more so. But the argument for the Feds climbing onboard makes more sense than ever.

 

Turning to Uncle Sam

It goes like this. Value medicine has, at its core, an emphasis on prevention. As the population gets older, workers look to extend their livelihood (in fact, the economy, at least in the near term, is depending on it). The ability of healthcare to maintain worker viability will be essential. And it will have to be done cost-effectively. That means keeping a lid on medical expenses.

Better healthcare, improved quality of life, lower costs — it’s a challenging hat trick. And it can’t be done without disease prevention. And in that screening will be enormously important.

Medical imaging already has the core tool sets upon which to build. The current — and evolving — approach to prostate assessment shows where screening could go. CT lung screening will be a significant step in the same direction only if other technologies are brought in to complement it.

Screening is too important to America’s future to bet on single paths of technological development. We cannot simply wait for the right technology to plop serendipitously into our collective lap.

Editor's note: This is the second blog in a four-part series on screening. The first blog, “Screening: How New Looks at Old Modalities Might Turn Imaging Upside Down,” can be found here.

Related Content

Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Carestream’s X-ray digital tomosynthesis functionality creates three-dimensional datasets from digital radiography (DR) that can be scrolled through similar to computed tomography (CT) imaging. It received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2020. Digital tomosynthesis uses a single sweep of X-ray exposures and streamlines operator workflow by separating the process of DT exposure acquisition from image volume formation.
News | Digital Radiography (DR) | January 15, 2020
January 15, 2020 — Carestream’s X-ray digital tomosynthesis (DT) functionality, which creates three-dimensional datas
Imaging Technology News (ITN) has been acquired by Wainscot Media
News | Imaging Technology News - ITN | January 14, 2020
January 14, 2020 — Park Ridge, N.J.-based publisher Wainscot Medi...
Videos | RSNA | January 13, 2020
ITN Editor Dave Fornell takes a tour of some of the most innovative new medical imaging technologies displayed on the
Partners of Collaborative Imaging experience billing collection improvements of over 25 percent while reducing operating costs by 30 percent

Image courtesy of Philips Healthcare

News | Radiology Business | January 08, 2020
January 8, 2020 — The $18 billion radiology industry continues to face a growing threat of consolidation, resulting i
Sponsored Content | Videos | Digital Radiography (DR) | January 06, 2020
An experienced technologist and two Agfa executives talk about what distinguishes the new Agfa 100s.
Sponsored Content | Videos | Ultrasound Imaging | January 06, 2020
The Arietta 850SE provides facilities with numerous features and functionality to get the most out of a system.
Sponsored Content | Videos | Computed Tomography (CT) | January 06, 2020
Hitachi announced the FDA clearance of its newest CT – Scenaria View – at RSNA2019.
The use of augmented and virtual reality in radiology was the subject of two articles and part of the HIMSS 2019 trends article in the top 25 list. Augmented reality is being looked at as a way to better train radiologists, allow surgeons to use medical imaging in true 3-D to better plan surgeries, and it can allow patients to better understand their conditions compared to use of traditional 2-D medical images. Photo by Dave Fornell.

The use of augmented and virtual reality in radiology was the subject of two articles and part of the HIMSS 2019 trends article in the top 25 list. Augmented reality is being looked at as a way to better train radiologists, allow surgeons to use medical imaging in true 3-D to better plan surgeries, and it can allow patients to better understand their conditions compared to use of traditional 2-D medical images. Photo by Dave Fornell.

Feature | Radiology Imaging | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 25 radiology articles on the Imaging Technology News (ITN) website from 2019 based